INDIAGLYCOIndia Glycols Ltd.

    India Glycols Q2 FY27 Results: Consolidated Net Profit ₹23.69 Crore on Total Income of ₹363 Crore

    • Earnings
    • Chemicals
    Pipework, storage tanks and a walkway at a chemical plant, behind a corrugated metal fence
    Illustrative image via Wikimedia Commons

    India Glycols (NSE: INDIAGLYCO) reported consolidated total income of ₹362.75 crore and net profit of ₹23.69 crore for the quarter ended 30 Sep 2026, it said in a filing on 13 Nov 2026. Standalone total income was ₹358.51 crore and standalone net profit ₹11.24 crore for the same quarter.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹362.75 crore, down 51.1% YoY and up 1.5% QoQ
    • Net profit and EPS: ₹23.69 crore, down 63.6% YoY; basic EPS ₹3.53 against ₹10.51
    • Finance costs: ₹12.07 crore, down 75.5% YoY and up 3.7% QoQ

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹358.51 crore, down 85.1% YoY and up 1.0% QoQ
    • Net profit and EPS: ₹11.24 crore, down 79.2% YoY; basic EPS ₹1.68 against ₹8.71
    • Finance costs: ₹12.07 crore, down 75.5% YoY and up 3.7% QoQ

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    362.75741.57-51.1%357.44+1.5%
    23.6965.06-63.6%32.59-27.3%
    EPS, basic (₹)3.5310.51-66.4%4.36-19.0%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    The year-on-year comparison is not like for like. The filing says the year-ago comparatives include the Spirits and Biofuel undertaking and the Biopharma undertaking, which were demerged with effect from 1 Apr 2026, and that the figures are not comparable with the current period. Consolidated total income fell 51.1% to ₹362.75 crore from ₹741.57 crore, while the June quarter stood at ₹357.44 crore, a rise of 1.5%.

    Net profit fell faster than income in both comparisons. Consolidated net profit fell 63.6% YoY and 27.3% QoQ, against income changes of -51.1% and +1.5%. Profit before tax of ₹27.70 crore is 66.9% below the year-ago ₹83.61 crore, and tax of ₹6.01 crore is 21.7% of that profit before tax.

    Consolidated results include the group's share of net profit after tax of ₹12.64 crore from a joint venture for the quarter, reviewed by another auditor. That share is larger than the consolidated net profit of ₹23.69 crore less the standalone figure of ₹11.24 crore, which is ₹12.45 crore. The consolidated other income of ₹0.33 crore is 0.1% of total income. Exceptional items for the quarter are nil.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    358.512,412.88-85.1%355.01+1.0%
    11.2453.94-79.2%12.35-9.0%
    EPS, basic (₹)1.688.71-80.7%1.84-8.7%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Standalone total income fell 85.1% YoY to ₹358.51 crore and rose 1.0% QoQ from ₹355.01 crore. Almost all of the year-on-year fall is in revenue from operations, which was ₹358.18 crore against ₹2,410.71 crore, while other income was ₹0.33 crore against ₹2.17 crore.

    Standalone net profit of ₹11.24 crore fell 79.2% YoY and 9.0% QoQ. Standalone finance costs of ₹12.07 crore are 3.4% of total income, against 2.0% a year earlier on the year-ago figures. Standalone tax expense of ₹6.01 crore is 39.4% of profit before tax of ₹15.25 crore, a higher share than the consolidated 21.7%.

    The filing states the auditors issued limited review reports with unmodified conclusions and drew attention to the demerger note. The company identified a single reportable segment, Bio-based Specialities and Performance Chemicals.

    Inference

    The filing says the Spirits and Biofuel and Biopharma undertakings were demerged into IGL Spirits Limited and Ennature Bio Pharma Limited, with effect from 1 Apr 2026, and that those companies ceased to be subsidiaries from the appointed date.

    Company context: Blacklitt's data shows market value of ₹2,086 crore at the 13 Nov 2026 close of ₹311.30 a share, and Q1 FY27 consolidated total income of ₹2,988.82 crore. Those figures are not comparable with this quarter, which excludes the demerged businesses.

    The filing does not state the reason for the fall in revenue and profit beyond the demerger, nor the basis for the split of tax between current and deferred tax in the quarter.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Related posts

    All India Glycols Ltd. articles